WO1998035985B1 - Protein markers for lung cancer and use thereof - Google Patents
Protein markers for lung cancer and use thereofInfo
- Publication number
- WO1998035985B1 WO1998035985B1 PCT/IB1998/000361 IB9800361W WO9835985B1 WO 1998035985 B1 WO1998035985 B1 WO 1998035985B1 IB 9800361 W IB9800361 W IB 9800361W WO 9835985 B1 WO9835985 B1 WO 9835985B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- animal
- human
- spot
- lung cancer
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title claims abstract 10
- 108090000623 proteins and genes Proteins 0.000 title claims abstract 10
- 208000020816 lung neoplasm Diseases 0.000 title claims 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 title claims 3
- 201000005202 lung cancer Diseases 0.000 title claims 3
- 208000037841 lung tumor Diseases 0.000 claims abstract 5
- 206010028980 Neoplasm Diseases 0.000 claims abstract 3
- 241001465754 Metazoa Species 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 230000002018 overexpression Effects 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 1
- 239000000872 buffer Substances 0.000 abstract 1
- 239000000499 gel Substances 0.000 abstract 1
Abstract
Computerized analysis of 2-D gels, both carrier ampholyte (CA) and immobilized pH gradient (IPG) based, of the proteins in tissue from lung tumors, reveals proteins which are different types of tumors and in control tissues.
Claims
AMENDED CLAIMS
[received by the International Bureau on 25 September 1998 (25.09.98); new claims 19-24 added, remaining claims unchanged (1 page)]
18. A method of treating a tumor in an animal or human in need thereof
comprising: a) exposing immunocompetent cells from the animal or human to at least
one protein selected from the group consisting of Spot 14, 15, 16, 17, 21 , 22, 27,
29, 31 , 33, 40, 42, 43, 47, 50, 53, 57, 58, 59, 61 , 62, 66, 67, 68, 73, 74, 79, 80,
81 , 83, 84, 86, 90, 92, 94, 95, 96, 97, 98, 100, 101 , 102, 105, 106, 107, and 109;
and b) injecting said immunocompetent cells into the animal or human to treat
a tumor.
19. A method for diagnosing lung cancer in an animal or human,
comprising detecting at least one protein which is overexpressed in lung tumors
in a sample from the animal or human, and correlating the detection of the
protein with the presence of lung tumor.
20. The method of claim 19, wherein the sample is serum.
21. The method of claim 19, wherein the at least one protein is spot 107
or spot 109.
22. A method for diagnosing lung cancer in an animal or human,
comprising detecting the overexpression of at least one protein which is
overexpressed in lung tumors in a sample from the animal or human, and
correlating the overexpression of the protein with the presence of lung tumor.
23. The method of claim 22, wherein the sample is serum.
24. The method of claim 22, wherein the at least one protein is spot 107
or spot 109.
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98905576A EP0961780B1 (en) | 1997-02-12 | 1998-02-12 | Protein markers for lung cancer and use thereof |
| JP53551498A JP4367866B2 (en) | 1997-02-12 | 1998-02-12 | Protein markers for lung cancer and uses thereof |
| NZ337750A NZ337750A (en) | 1997-02-12 | 1998-02-12 | Protein markers for lung cancer and use thereof |
| DK98905576T DK0961780T3 (en) | 1997-02-12 | 1998-02-12 | Protein markers for lung cancer and its use |
| AU61112/98A AU6111298A (en) | 1997-02-12 | 1998-02-12 | Protein markers for lung cancer and use thereof |
| CA2280930A CA2280930C (en) | 1997-02-12 | 1998-02-12 | Protein markers for lung cancer and use thereof |
| DE69837529T DE69837529T2 (en) | 1997-02-12 | 1998-02-12 | PROTEIN MARKERS FOR LUNG CANCER AND ITS USE |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3881997P | 1997-02-12 | 1997-02-12 | |
| US60/038,819 | 1997-02-12 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1998035985A1 WO1998035985A1 (en) | 1998-08-20 |
| WO1998035985B1 true WO1998035985B1 (en) | 1998-11-12 |
Family
ID=21902087
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB1998/000361 WO1998035985A1 (en) | 1997-02-12 | 1998-02-12 | Protein markers for lung cancer and use thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20020192228A1 (en) |
| EP (1) | EP0961780B1 (en) |
| JP (1) | JP4367866B2 (en) |
| AT (1) | ATE359515T1 (en) |
| AU (1) | AU6111298A (en) |
| CA (1) | CA2280930C (en) |
| DE (1) | DE69837529T2 (en) |
| DK (1) | DK0961780T3 (en) |
| ES (1) | ES2284200T3 (en) |
| NZ (1) | NZ337750A (en) |
| WO (1) | WO1998035985A1 (en) |
Families Citing this family (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6660838B1 (en) | 1998-03-18 | 2003-12-09 | Corixa Corporation | Compounds and methods for therapy and diagnosis of lung cancer |
| US6737514B1 (en) | 1998-12-22 | 2004-05-18 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US6960570B2 (en) | 1998-03-18 | 2005-11-01 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US6696247B2 (en) | 1998-03-18 | 2004-02-24 | Corixa Corporation | Compounds and methods for therapy and diagnosis of lung cancer |
| US7579160B2 (en) | 1998-03-18 | 2009-08-25 | Corixa Corporation | Methods for the detection of cervical cancer |
| US6706262B1 (en) | 1998-03-18 | 2004-03-16 | Corixa Corporation | Compounds and methods for therapy and diagnosis of lung cancer |
| US6426072B1 (en) | 2000-08-02 | 2002-07-30 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US7258860B2 (en) | 1998-03-18 | 2007-08-21 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US6821518B1 (en) | 1998-03-18 | 2004-11-23 | Corixa Corporation | Compounds and methods for therapy and diagnosis of lung cancer |
| US6518256B1 (en) | 1998-03-18 | 2003-02-11 | Corixa Corporation | Compounds and methods for therapy and diagnosis of lung cancer |
| US6482597B1 (en) | 1999-12-17 | 2002-11-19 | Corixa Corporation | Compounds and methods for therapy and diagnosis of lung cancer |
| US6312695B1 (en) | 1998-03-18 | 2001-11-06 | Corixa Corporation | Compounds and methods for therapy of lung cancer |
| US7049063B2 (en) | 1998-03-18 | 2006-05-23 | Corixa Corporation | Methods for diagnosis of lung cancer |
| US6531315B1 (en) | 1998-03-18 | 2003-03-11 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| AU2004201392B2 (en) * | 1998-11-05 | 2007-06-14 | The Regents Of The University Of Michigan | S100 proteins and autoantibodies as serum markers for cancer |
| AU773265B2 (en) * | 1998-11-05 | 2004-05-20 | Regents Of The University Of Michigan, The | S100 proteins and autoantibodies as serum markers for cancer |
| EP1169347B1 (en) * | 1999-04-02 | 2008-07-02 | Corixa Corporation | Compounds and methods for therapy and diagnosis of lung cancer |
| EP1250149A4 (en) | 1999-11-22 | 2003-06-04 | Diadexus Inc | A novel method of diagnosing, monitoring, staging, imaging and treating cancer |
| IL155611A0 (en) * | 2000-11-02 | 2003-11-23 | Molecular Discoveries L L C | Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (sclc) |
| EP1373896A2 (en) * | 2001-03-12 | 2004-01-02 | MonoGen, Inc. | Cell-based detection and differentiation of disease states |
| WO2004004770A1 (en) * | 2002-07-05 | 2004-01-15 | Universite Laval | Chemotactic factor inhibitor for modulating inflammatory reactions |
| AU2002951153A0 (en) * | 2002-09-02 | 2002-09-19 | Proteome Systems Intellectual Property Pty Ltd | An electrophoresis gel having improved swelling properties |
| TWI454275B (en) * | 2004-05-11 | 2014-10-01 | Abgenomics Cooperatief Ua | T-cell death-inducing epitopes |
| CA2573596A1 (en) * | 2004-07-13 | 2006-01-19 | Universite Laval | S100 protein inhibitors for treating leukemia |
| US7659087B2 (en) | 2004-07-23 | 2010-02-09 | Aspenbio Pharma, Inc. | Methods and devices for diagnosis of appendicitis |
| TR200700896T1 (en) | 2004-07-23 | 2007-04-24 | Aspenbio, Inc. | Methods and devices for the diagnosis of appendicitis |
| PL2364973T3 (en) | 2005-05-18 | 2014-12-31 | Array Biopharma Inc | Heterocyclic inhibitors of mek and methods of use thereof |
| KR100732298B1 (en) * | 2005-11-24 | 2007-06-25 | 이화여자대학교 산학협력단 | Cancer metastasis diagnostic composition using ubiquitin C-terminal hydrolyzate-L1 |
| TW200813091A (en) | 2006-04-10 | 2008-03-16 | Amgen Fremont Inc | Targeted binding agents directed to uPAR and uses thereof |
| CL2007002225A1 (en) | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | SPECIFIC UNION AGENT FOR A RECEIVER OF THE GROWTH FACTOR DERIVED FROM PLATES (PDGFR-ALFA); NUCLEIC ACID MOLECULA THAT CODIFIES IT; VECTOR AND CELL GUESTS THAT UNDERSTAND IT; CONJUGADO UNDERSTANDING THE AGENT; AND USE OF THE AGENT OF A |
| EP2057156B1 (en) | 2006-08-23 | 2017-02-01 | KuDOS Pharmaceuticals Limited | 2-methylmorpholine pyrido-,pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors |
| PE20081887A1 (en) | 2007-03-20 | 2009-01-16 | Dainippon Sumitomo Pharma Co | NEW ADENINE COMPOUND |
| US8044056B2 (en) | 2007-03-20 | 2011-10-25 | Dainippon Sumitomo Pharma Co., Ltd. | Adenine compound |
| EP2781913B1 (en) * | 2007-09-11 | 2017-12-13 | Cancer Prevention And Cure, Ltd. | Method for aiding in the diagnosis and therapy of asthma and lung cancer |
| PL2201012T3 (en) | 2007-10-11 | 2014-11-28 | Astrazeneca Ab | Pyrrolo[2,3-d]pyrimidin derivatives as protein kinase b inhibitors |
| NZ586802A (en) | 2007-12-19 | 2012-03-30 | Genentech Inc | Imidazo[1,5-a]pyridine and imidazo[1,5-a]pyrazine derivatives for the treatment of inflammatory diseases |
| US8486963B2 (en) | 2007-12-21 | 2013-07-16 | Genentech, Inc. | Azaindolizines and methods of use |
| AU2009294415B2 (en) | 2008-09-19 | 2015-09-24 | Medimmune Llc | Antibodies directed to DLL4 and uses thereof |
| TW201028410A (en) | 2008-12-22 | 2010-08-01 | Astrazeneca Ab | Chemical compounds 610 |
| CA2748158A1 (en) | 2008-12-23 | 2010-07-01 | Astrazeneca Ab | Targeted binding agents directed to .alpha.5.beta.1 and uses thereof |
| SG10201706294VA (en) | 2009-02-05 | 2017-09-28 | Immunogen Inc | Novel benzodiazepine derivatives |
| EP2857522A3 (en) | 2009-03-12 | 2015-10-14 | Cancer Prevention And Cure, Ltd. | Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender-based disease identification, assessment, prevention and therapy |
| CA2755061A1 (en) | 2009-03-13 | 2010-09-16 | Cellzome Limited | Pyrimidine derivatives as mtor inhibitors |
| US20120040955A1 (en) | 2009-04-14 | 2012-02-16 | Richard John Harrison | Fluoro substituted pyrimidine compounds as jak3 inhibitors |
| US8389580B2 (en) | 2009-06-02 | 2013-03-05 | Duke University | Arylcyclopropylamines and methods of use |
| EP2475648A1 (en) | 2009-09-11 | 2012-07-18 | Cellzome Limited | Ortho substituted pyrimidine compounds as jak inhibitors |
| CN102666545B (en) | 2009-10-20 | 2016-04-06 | 塞尔卓姆有限公司 | As the heterocycle Pyrazolopyrimidine analogs of JAK inhibitor |
| US8779108B2 (en) | 2009-11-24 | 2014-07-15 | Medimmune, Limited | Targeted binding agents against B7-H1 |
| WO2011068233A1 (en) | 2009-12-03 | 2011-06-09 | Dainippon Sumitomo Pharma Co., Ltd. | Imidazoquinolines which act via toll - like receptors (tlr) |
| WO2011085163A2 (en) * | 2010-01-08 | 2011-07-14 | The Regents Of The University Of California | Protein markers for lung cancer detection and methods of using thereof |
| MX341687B (en) | 2010-02-10 | 2016-08-30 | Immunogen Inc | Cd20 antibodies and uses thereof. |
| US9249129B2 (en) | 2010-03-04 | 2016-02-02 | Cellzome Limited | Morpholino substituted urea derivatives as mTOR inhibitors |
| BR112012027803A2 (en) | 2010-04-30 | 2016-08-09 | Cellzome Ltd | pyrazole compounds as jak inhibitors |
| SA111320519B1 (en) | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | Pyrimidinyl compounds for use as ATR inhibitors |
| EP2588105A1 (en) | 2010-07-01 | 2013-05-08 | Cellzome Limited | Triazolopyridines as tyk2 inhibitors |
| JP2013534233A (en) | 2010-08-20 | 2013-09-02 | セルゾーム リミティッド | Heterocyclylpyrazolopyrimidine analogs as selective JAK inhibitors |
| JP2014500254A (en) | 2010-11-09 | 2014-01-09 | セルゾーム リミティッド | Pyridine compounds and their aza analogs as TYK2 inhibitors |
| ES2717657T3 (en) | 2011-02-15 | 2019-06-24 | Immunogen Inc | Methods for the preparation of conjugates |
| JP5937112B2 (en) | 2011-02-17 | 2016-06-22 | カンサー・セラピューティクス・シーアールシー・プロプライエタリー・リミテッドＣａｎｃｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｒｃ Ｐｔｙ Ｌｉｍｉｔｅｄ | Selective FAK inhibitor |
| AU2012216893B2 (en) | 2011-02-17 | 2016-08-11 | Cancer Therapeutics Crc Pty Limited | FAK inhibitors |
| JP2014510122A (en) | 2011-04-04 | 2014-04-24 | セルゾーム リミテッド | Dihydropyrrolopyrimidine derivatives as mTOR inhibitors |
| WO2012143320A1 (en) | 2011-04-18 | 2012-10-26 | Cellzome Limited | (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors |
| WO2013014162A1 (en) | 2011-07-28 | 2013-01-31 | Cellzome Limited | Heterocyclyl pyrimidine analogues as jak inhibitors |
| WO2013017479A1 (en) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
| WO2013017480A1 (en) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
| JP2014531449A (en) | 2011-09-20 | 2014-11-27 | セルゾーム リミティッド | Pyrazolo [4,3-c] pyridine derivatives as kinase inhibitors |
| CA2849189A1 (en) | 2011-09-21 | 2013-03-28 | Cellzome Limited | Morpholino substituted urea or carbamate derivatives as mtor inhibitors |
| BR112014008241A2 (en) | 2011-10-07 | 2017-04-18 | Cellzome Ltd | compound, pharmaceutical composition, methods for treating, controlling, retarding or preventing disease and disorder, and for preparing a compound, and use of a compound |
| US20130178520A1 (en) | 2011-12-23 | 2013-07-11 | Duke University | Methods of treatment using arylcyclopropylamine compounds |
| CA2860095A1 (en) | 2011-12-23 | 2013-06-27 | Cellzome Limited | Pyrimidine-2,4-diamine derivatives as kinase inhibitors |
| CN104583235B (en) | 2012-06-08 | 2019-03-01 | 苏特罗生物制药公司 | Antibodies containing site-specific unnatural amino acid residues, methods of making and using the same |
| US9732161B2 (en) | 2012-06-26 | 2017-08-15 | Sutro Biopharma, Inc. | Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use |
| AU2013302320A1 (en) | 2012-08-17 | 2015-02-26 | Cancer Therapeutics Crc Pty Limited | VEGFR3 inhibitors |
| WO2014031566A1 (en) | 2012-08-22 | 2014-02-27 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives |
| SG11201501464TA (en) | 2012-08-31 | 2015-03-30 | Sutro Biopharma Inc | Modified amino acids comprising an azido group |
| WO2014041349A1 (en) | 2012-09-12 | 2014-03-20 | Cancer Therapeutics Crc Pty Ltd | Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors |
| WO2014045101A1 (en) | 2012-09-21 | 2014-03-27 | Cellzome Gmbh | Tetrazolo quinoxaline derivatives as tankyrase inhibitors |
| JP6423804B2 (en) | 2013-02-28 | 2018-11-14 | イミュノジェン・インコーポレーテッド | Complex containing cell binding agent and cytotoxic agent |
| EP2961434A2 (en) | 2013-02-28 | 2016-01-06 | ImmunoGen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
| AR095443A1 (en) | 2013-03-15 | 2015-10-14 | Fundación Centro Nac De Investig Oncológicas Carlos Iii | HEREROCICLES CONDENSED WITH ACTION ON ATR |
| WO2014194030A2 (en) | 2013-05-31 | 2014-12-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
| WO2015006555A2 (en) | 2013-07-10 | 2015-01-15 | Sutro Biopharma, Inc. | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| US9840493B2 (en) | 2013-10-11 | 2017-12-12 | Sutro Biopharma, Inc. | Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use |
| GB201510019D0 (en) | 2015-06-09 | 2015-07-22 | Cancer Therapeutics Crc Pty Ltd | Compounds |
| EP3407917A1 (en) | 2016-01-27 | 2018-12-05 | Sutro Biopharma, Inc. | Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates |
| CN107459519A (en) | 2016-06-06 | 2017-12-12 | 上海艾力斯医药科技有限公司 | Annelated pyrimidines piperidines ring derivatives and its preparation method and application |
| EP3507305A1 (en) | 2016-09-02 | 2019-07-10 | Dana-Farber Cancer Institute, Inc. | Composition and methods of treating b cell disorders |
| CN110177780B (en) | 2016-12-05 | 2022-11-01 | 阿普罗斯治疗公司 | Pyrimidine compounds containing acidic groups |
| US10786502B2 (en) | 2016-12-05 | 2020-09-29 | Apros Therapeutics, Inc. | Substituted pyrimidines containing acidic groups as TLR7 modulators |
| CA3058481A1 (en) | 2017-04-04 | 2018-10-11 | Lung Cancer Proteomics, Llc | Plasma based protein profiling for early stage lung cancer prognosis |
| WO2019023316A1 (en) | 2017-07-26 | 2019-01-31 | Sutro Biopharma, Inc. | Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma |
| MA50265A (en) | 2017-09-18 | 2020-07-29 | Sutro Biopharma Inc | ALPHA ANTI-FOLATE ANTIBODY-RECEPTOR CONJUGATES AND THEIR USES |
| NL2019801B1 (en) | 2017-10-25 | 2019-05-02 | Univ Leiden | Delivery vectors |
| CN112513031A (en) | 2018-06-04 | 2021-03-16 | 阿普罗斯治疗公司 | Acid group containing pyrimidine compounds useful for the treatment of diseases associated with the modulation of TLR7 |
| GB201810092D0 (en) | 2018-06-20 | 2018-08-08 | Ctxt Pty Ltd | Compounds |
| GB201810581D0 (en) | 2018-06-28 | 2018-08-15 | Ctxt Pty Ltd | Compounds |
| JP2022500454A (en) | 2018-09-17 | 2022-01-04 | ストロ バイオファーマ インコーポレーテッド | Combination therapy with antifolate receptor antibody conjugate |
| WO2020227105A1 (en) | 2019-05-03 | 2020-11-12 | Sutro Biopharma, Inc. | Anti-bcma antibody conjugates |
| JP2022545930A (en) | 2019-08-31 | 2022-11-01 | 上海奕拓醫藥科技有限責任公司 | Pyrazole derivative as FGFR inhibitor and method for preparing the same |
| EP4114852A1 (en) | 2020-03-03 | 2023-01-11 | Sutro Biopharma, Inc. | Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use |
| AU2023300170A1 (en) | 2022-06-30 | 2025-01-09 | Sutro Biopharma, Inc. | Anti-ror1 antibodies and antibody conjugates, compositions comprising anti-ror1 antibodies or antibody conjugates, and methods of making and using anti-ror1 antibodies and antibody conjugates |
| WO2025081117A2 (en) | 2023-10-13 | 2025-04-17 | Sutro Biopharma, Inc. | Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK276185D0 (en) * | 1984-11-09 | 1985-06-19 | Novo Industri As | MONOCLONAL ANTIBODIES, METHOD OF PREPARING THESE AND THEIR DIAGNOSTIC USES |
| US5019497A (en) * | 1984-11-09 | 1991-05-28 | Lennart Olsson | Human squamous lung carcinoma cell specific antigens and antibodies |
| US5171665A (en) * | 1989-04-17 | 1992-12-15 | Oncogen | Monoclonal antibody to novel antigen associated with human tumors |
| CH685959A5 (en) * | 1992-08-24 | 1995-11-15 | Biomedicals Ag | Diagnostic test kit for the determination of proteins. |
| EP0695760A1 (en) * | 1994-08-05 | 1996-02-07 | F. Hoffmann-La Roche Ag | Novel tumor marker for lung cancer |
| US6107103A (en) * | 1996-10-15 | 2000-08-22 | Procyon Bropharma Inc. | Assay for PSP94 protein |
-
1998
- 1998-02-12 DK DK98905576T patent/DK0961780T3/en active
- 1998-02-12 AU AU61112/98A patent/AU6111298A/en not_active Abandoned
- 1998-02-12 ES ES98905576T patent/ES2284200T3/en not_active Expired - Lifetime
- 1998-02-12 US US09/022,527 patent/US20020192228A1/en not_active Abandoned
- 1998-02-12 WO PCT/IB1998/000361 patent/WO1998035985A1/en active IP Right Grant
- 1998-02-12 JP JP53551498A patent/JP4367866B2/en not_active Expired - Fee Related
- 1998-02-12 AT AT98905576T patent/ATE359515T1/en active
- 1998-02-12 EP EP98905576A patent/EP0961780B1/en not_active Expired - Lifetime
- 1998-02-12 DE DE69837529T patent/DE69837529T2/en not_active Expired - Lifetime
- 1998-02-12 NZ NZ337750A patent/NZ337750A/en not_active IP Right Cessation
- 1998-02-12 CA CA2280930A patent/CA2280930C/en not_active Expired - Fee Related
-
2003
- 2003-06-16 US US10/461,424 patent/US20050095249A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1998035985B1 (en) | Protein markers for lung cancer and use thereof | |
| DE69837529D1 (en) | PROTEIN MARKERS FOR LUNG CANCER AND ITS USE | |
| TAYLOR et al. | Immunofluorescent localization of vitamin D-dependent calcium-binding protein | |
| Ralston et al. | The product of the protooncogene c-src is modified during the cellular response to platelet-derived growth factor. | |
| Fitzgerald et al. | Inhibition of intercellular communication by tumor-promoting phorbol esters | |
| DE69519796D1 (en) | PTPalpha determination in tumor diagnosis and prognosis | |
| EA200501772A1 (en) | METHODS OF MEASURING THE EXPRESSION OF GENES FROM FIXED AND PARULIN FABRIC SAMPLE | |
| AU2001253079A1 (en) | Methods, compositions and kits for the detection and monitoring of breast cancer | |
| EP0762885A4 (en) | GLOBAL MITOGENIC FACTORS, PREPARATION AND USE | |
| Evans et al. | Gene-specific DNA repair in xeroderma pigmentosum complementation groups A, C, D, and F. Relation to cellular survival and clinical features. | |
| SE9500023D0 (en) | Method of detecting cancer | |
| Brock | Morphological and biochemical criteria for the separation of Cardium glaucum (Bruguiere) from Cardium edule (L.) | |
| EA200000845A1 (en) | GENE ENCODING NEW CANCER MARKER | |
| DE60044350D1 (en) | PROSTATE SPECIFIC GEN PCGEM1 AND METHODS OF USE FOR THE RECOGNITION, TREATMENT AND PREVENTION OF PROSTATE CANCER | |
| CA2221495A1 (en) | Methods and uses for apoptin | |
| HUT72700A (en) | Method for in vitro quantitative assessment of protein activity related multidrug resistance of tumors in biological samples | |
| CA2366523A1 (en) | Method for analyzing the amount of intraabdominal adipose tissue | |
| Holloway et al. | Localisation and expression of metallothionein immunoreactivity in the developing sheep brain | |
| Presta et al. | Human placental tissue stimulates bovine capillary endothelial cell growth, migration and protease production | |
| CA2264963A1 (en) | Protein markers for esophageal cancer | |
| DE69636041D1 (en) | IDENTIFICATION OF BREAST TUMORVIRUS-TYPE SEQUENCES IN BREAST CANCER IN HUMANS | |
| DE69734199D1 (en) | HUMAN NETRIN-1 | |
| Tofilon et al. | BCNU-induced sister chromatid exchanges are increased by X irradiation | |
| CA2415923A1 (en) | Novel tumor antigen useful in diagnosis and therapy of bladder, ovary, lung and kidney cancers | |
| BR0115689A (en) | Nucleic acid and polypeptide differentiation inhibitor expression analysis useful in the diagnosis and treatment of prostate cancer |